Download Files:
Products Details
Product Description
– Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters[1]. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[2]. Laniquidar has limited oral bioavailability[3].
Web ID
– HY-132189
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C37H36N4O3
References
– [1]Luurtsema G, et al. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9. |[2]Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51. |[3]Fox E, et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59.
CAS Number
– 197509-46-9
Molecular Weight
– 584.71
SMILES
– O=C(C1=CN=C2/C(C3=C(CCN21)C=CC=C3)=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=C(C=C6)C=CC=C7)OC
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– P-glycoprotein
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
